TY  - GEN
AU  - De Falco,Valentina
AU  - De Falco,Valentina
TI  - Targeted Cancer Therapy and Mechanisms of Resistance
SN  - books978-3-0365-2856-4
PY  - 2022///
CY  - Basel
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - Research & information: general
KW  - bicssc
KW  - Biology, life sciences
KW  - 3D spheroids
KW  - photothermy
KW  - gold nanoparticles
KW  - doxorubicin resistance
KW  - colorectal cancer
KW  - cellular prion protein
KW  - PrPC
KW  - PRNP
KW  - cancer
KW  - cancer stem cell
KW  - targeted cancer therapy
KW  - brain metastases
KW  - treatment
KW  - non-small cell lung carcinoma
KW  - EGFR
KW  - ALK
KW  - immunotherapy
KW  - HDAC6
KW  - bortezomib-resistance
KW  - HDAC6-selective inhibitor
KW  - bortezomib
KW  - carfilzomib
KW  - multiple myeloma
KW  - LMP2
KW  - combination therapy
KW  - colorectal cancer cells
KW  - drug resistance
KW  - 5-Fluorouracil
KW  - thymidylate synthase
KW  - exome sequencing
KW  - CD47
KW  - immune activation
KW  - pro-tumoral macrophages
KW  - breast cancer
KW  - polo-like kinase 1 (PLK1)
KW  - pyrazole
KW  - quantitative structure-activity relationship
KW  - hybridization
KW  - ovarian cancer
KW  - cisplatin
KW  - cisplatin resistance
KW  - PARPi
KW  - niraparib
KW  - Twist
KW  - lethality
KW  - AF4
KW  - cell culture
KW  - FGFR2
KW  - HOXA9
KW  - MLL-AF4
KW  - nucleus
KW  - target therapy
KW  - t(4
KW  - 11) leukemia
KW  - radiation-resistant
KW  - cell death
KW  - ERK
KW  - EMT
KW  - cancer stem cells (CSCs)
KW  - PD98059
KW  - PARP inhibitors
KW  - PARP inhibitor resistance
KW  - signal transduction networks
KW  - pathways
KW  - event-free survival
KW  - biomarkers
KW  - WNT pathway
KW  - targeted therapy
KW  - Wee1 kinase
KW  - cell cycle
KW  - tumor resistance
KW  - lenvatinib
KW  - sorafenib-resistant
KW  - hepatocellular carcinoma
KW  - FGFR4
KW  - autophagy
KW  - microRNA
N1  - Open Access
N2  - Tumor cells commonly exhibit dependence on a single activated oncogenic pathway or protein to maintain their malignant proliferation and survival, a phenomenon called "oncogene addiction". According to this concept, protein kinases have been identified as promising molecular targets for cancer therapy. There are several possibilities for targeting these proteins in cancer, including monoclonal antibodies, compounds able to favor the proteolytic degradation of the kinase, small-molecule protein kinase inhibitors (PKIs). Moreover, new anticancer treatments have increasingly been developed focusing on tumor suppressor genes and RNA interference. Despite promising results in cancer treatment with targeted cancer drugs, clinical experience has shown that only a fraction of patients respond to targeted therapies, even if their tumor expresses the altered target. This is known as primary resistance. Otherwise, secondary or acquired resistance to the treatment arises, almost invariably, when tumors are treated with cancer drugs. We set out to select some studies containing emerging developments on the subject. In essence, this collection aims to highlight some recent findings regarding resistance mechanisms and reviews of molecular targeting and resistance with 14 contributions, including 10 original research papers and 4 reviews. Aspects relating to solid cancers, such as breast, ovary, colon, and blood cancers such as leukemia, and the identification of resistance mechanisms and new molecular targets, help to create the basis for the preclinical and clinical development of more effective next-generation drugs
UR  - https://mdpi.com/books/pdfview/book/4826
UR  - https://directory.doabooks.org/handle/20.500.12854/78735
ER  -